- Home
- MSW vs ZBIO Comparison
MSW vs ZBIO Comparison
Compare MSW & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSW
- ZBIO
- Stock Information
- Founded
- MSW 2012
- ZBIO 2019
- Country
- MSW Hong Kong
- ZBIO United States
- Employees
- MSW N/A
- ZBIO N/A
- Industry
- MSW
- ZBIO
- Sector
- MSW
- ZBIO
- Exchange
- MSW NYSE
- ZBIO NYSE
- Market Cap
- MSW 62.8M
- ZBIO 389.2M
- IPO Year
- MSW 2024
- ZBIO 2024
- Fundamental
- Price
- MSW $4.34
- ZBIO $10.41
- Analyst Decision
- MSW
- ZBIO Strong Buy
- Analyst Count
- MSW 0
- ZBIO 7
- Target Price
- MSW N/A
- ZBIO $32.29
- AVG Volume (30 Days)
- MSW 136.8K
- ZBIO 221.4K
- Earning Date
- MSW 08-25-2025
- ZBIO 08-16-2025
- Dividend Yield
- MSW N/A
- ZBIO N/A
- EPS Growth
- MSW 18.78
- ZBIO N/A
- EPS
- MSW 0.20
- ZBIO N/A
- Revenue
- MSW $31,769,612.00
- ZBIO $15,000,000.00
- Revenue This Year
- MSW N/A
- ZBIO $206.00
- Revenue Next Year
- MSW N/A
- ZBIO $41.92
- P/E Ratio
- MSW $22.16
- ZBIO N/A
- Revenue Growth
- MSW 30.91
- ZBIO N/A
- 52 Week Low
- MSW $2.12
- ZBIO $5.83
- 52 Week High
- MSW $10.58
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- MSW N/A
- ZBIO N/A
- Support Level
- MSW N/A
- ZBIO N/A
- Resistance Level
- MSW N/A
- ZBIO N/A
- Average True Range (ATR)
- MSW 0.00
- ZBIO 0.00
- MACD
- MSW 0.00
- ZBIO 0.00
- Stochastic Oscillator
- MSW 0.00
- ZBIO 0.00
About MSW MING SHING GROUP HOLDINGS LIMITED
Ming Shing Group Holdings Ltd is a holding company, which is primarily operated through its indirectly wholly-owned Hong Kong Operating Subsidiaries, MS (HK) Engineering Limited and MS Engineering Co., Limited. It is engaged in wet trades works, such as plastering works, tile laying works, brick laying works, floor screeding works and marble works. the company is mainly engaged in private-sector projects in Hong Kong. Its private sector projects mainly involve private residential developments and commercial developments. The project owners of its private sector projects are generally property developers, and its customers are generally main contractors and wet trades work subcontractors engaged under such projects.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.